Avidity Biosciences, Inc. - Common Stock (RNA) — AI analysis & news
Avidity Biosciences, Inc. - Common Stock (RNA) stock: 7 recent news items, slightly positive aggregate sentiment, AI analysis and market context on…
Current sentiment read
Across the last 7 indexed RNA stories, aggregate finance-aware sentiment is slightly positive (+0.29 on a -1 to +1 scale).
Latest RNA news
- Merck Animal Health SVP: to promote human health, invest in protecting animals · Fortune
- Germany's Merck buys Silence Therapeutics in $1.3 billion RNA drug deal - Reuters · Reuters
- Merck KGaA buys Silence in $1.3B deal after siRNA drug's phase 2 blood cancer win - Fierce Biotech · Fierce Biotech
- Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany - Business Wire · Business Wire
- Why AI Isn’t Ready to Tackle Our Convoluted Genomes · Wired
- Novartis Inks Chinese mRNA-Therapy Deal for Up to $7.8 Billion · Bloomberg
- Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters - Fierce Pharma · Fierce Pharma
FAQ
What is the current sentiment for RNA stock?
Aggregate finance-aware sentiment across the last 7 indexed RNA news stories is slightly positive (+0.29 on a -1 to +1 scale).